Summit trims size of offering:
This article was originally published in Clinica
Summit Technology is to scale back its public offering to 3.5 million shares, priced at $16.00. The Waltham, Massachusetts-based company, whose share price soared to more than $29.00 last month, following the FDA advisory panel recommendation for its LASIK vision correction laser, is presently trading at around the offer price. The company plans to use the funds to commercialise its LADAR radar eye tracking and narrow beam lens shaping technology. Initially it planned to offer four million shares.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.